Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 4/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 2/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593076 | 0.91 | ACHE (0.39) | NR1H2ACACBHTR6MEN1KMT2A | |
| SCHEMBL29836556 | 0.91 | ACHE (0.39) | NR1H2ACACBHTR6MEN1KMT2A | |
| SCHEMBL21593118 | 0.90 | NR1H2 (0.36) | NR1H2ACACBHTR6GPR119NAMPT | |
| SCHEMBL21593191 | 0.90 | NR1H2 (0.38) | NR1H2ACACBWNT3AHTR6MEN1 | |
| SCHEMBL21593119 | 0.89 | HCRTR2 (0.36) | NR1H2ACACBWNT3AHTR6MEN1 | |
| SCHEMBL21593189 | 0.88 | NR1H2 (0.37) | NR1H2ACACBWNT3AHTR6MEN1 | |
| SCHEMBL21593108 | 0.88 | NR1H2 (0.42) | NR1H2ACACBHTR6ESR2GPR119 | |
| SCHEMBL29836554 | 0.87 | NR1H2 (0.38) | NR1H2WNT3AMAPTIGF1R | |
| SCHEMBL21593192 | 0.87 | NR1H2 (0.38) | NR1H2WNT3AMAPTIGF1R | |
| SCHEMBL23762101 | 0.87 | BCL2 (0.36) | NR1H2ACACBMEN1KMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | NR1H2 1422/4885ACACB 2494/4885WNT3A 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.